A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate technetium-99m (99mTc) pertechnetate produced by a
cyclotron as a replacement for 99mTc pertechnetate obtained from a generator containing the
parent isotope Molybdenum-99 (99Mo). 99mTc pertechnetate is currently used in nuclear
medicine departments across the country. 99Mo is produced by a number of ageing nuclear
reactors across the world and severe shortages of the isotope have occurred in the past few
years. Cyclotron-produced 99mTc offers an alternative decentralized production method on a
regional basis. Since the manufacturing process is different, the safety and efficacy of
cyclotron-produced 99mTc pertechnetate must be evaluated in human subjects to enable its
routine clinical use.
Phase:
N/A
Details
Lead Sponsor:
British Columbia Cancer Agency
Collaborators:
Canadian Institutes of Health Research (CIHR) Centre for Probe Development and Commercialization Lawson Health Research Institute Natural Resources, Canada TRIUMF